Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 437

1.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Aug 9. doi: 10.1001/jamaoncol.2018.2961. [Epub ahead of print]

PMID:
30098165
2.

Role of the RANK/RANKL Pathway in Multiple Myeloma.

Raje NS, Bhatta S, Terpos E.

Clin Cancer Res. 2018 Aug 9. pii: clincanres.1537.2018. doi: 10.1158/1078-0432.CCR-18-1537. [Epub ahead of print]

PMID:
30093448
3.

Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis.

Polyzos SA, Terpos E.

Endocrine. 2018 Aug 3. doi: 10.1007/s12020-018-1699-9. [Epub ahead of print] No abstract available.

PMID:
30074171
4.

Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

Haematologica. 2018 Jul 26. pii: haematol.2018.191288. doi: 10.3324/haematol.2018.191288. [Epub ahead of print]

5.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Jul 23. doi: 10.1038/s41375-018-0209-7. [Epub ahead of print] Review.

PMID:
30038381
6.

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators.

Clin Lymphoma Myeloma Leuk. 2018 Jun 25. pii: S2152-2650(18)30230-1. doi: 10.1016/j.clml.2018.06.018. [Epub ahead of print]

7.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Jul 20. doi: 10.1111/ejh.13147. [Epub ahead of print]

PMID:
30027641
8.

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.

Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, Dimopoulos MA.

Leukemia. 2018 Jul 19. doi: 10.1038/s41375-018-0197-7. [Epub ahead of print]

PMID:
30026568
9.

Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8.

PMID:
29943159
10.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Apr 25. doi: 10.1038/s41375-018-0142-9. [Epub ahead of print] Review.

PMID:
29880892
11.

The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis.

Tsartsalis AN, Lambrou GI, Tsartsalis D, Savvidis C, Karantza M, Terpos E, Kanaka-Gantenbein C, Chrousos GP, Kattamis A.

Hormones (Athens). 2018 Jun;17(2):153-166. doi: 10.1007/s42000-018-0019-3. Epub 2018 May 2. Review.

12.

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, Tsitsilonis O, Dimopoulos MA.

Blood Cancer J. 2018 May 24;8(5):46. doi: 10.1038/s41408-018-0086-3. No abstract available.

13.

Optimizing therapy in bortezomib-exposed patients with multiple myeloma.

Migkou M, Gavriatopoulou M, Terpos E, Dimopoulos MA.

Expert Rev Hematol. 2018 Jun;11(6):463-469. doi: 10.1080/17474086.2018.1479637. Epub 2018 May 28.

PMID:
29788798
14.

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?

Terpos E, Suzan F, Goldschmidt H.

Crit Rev Oncol Hematol. 2018 Jun;126:19-23. doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29. Review.

15.

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Erratum in: Ann Hematol. 2018 Jun 26;:.

PMID:
29756171
16.

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

Terpos E, Ntanasis-Stathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Dimopoulos MA.

Blood Cancer J. 2018 May 11;8(5):42. doi: 10.1038/s41408-018-0075-6.

17.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2018 May 9:1-9. doi: 10.1080/10428194.2018.1459609. [Epub ahead of print]

PMID:
29741423
18.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 May 2. doi: 10.1038/s41375-018-0040-1. [Epub ahead of print] Review.

19.

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.

Papanagnou ED, Terpos E, Kastritis E, Papassideri IS, Tsitsilonis OE, Dimopoulos MA, Trougakos IP.

Oncotarget. 2018 Apr 3;9(25):17797-17809. doi: 10.18632/oncotarget.24882. eCollection 2018 Apr 3.

20.

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.

Eleutherakis-Papaiakovou E, Kastritis E, Gavriatopoulou M, Christoulas D, Roussou M, Ntanasis-Stathopoulos I, Kanellias N, Papatheodorou A, Dimopoulos MA, Terpos E.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):431-437. doi: 10.1016/j.clml.2018.03.010. Epub 2018 Mar 31.

PMID:
29685422
21.

Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study.

von Moos R, Body JJ, Guenther O, Terpos E, Acklin YP, Finek J, Pereira J, Maniadakis N, Hechmati G, Talbot S, Sleeboom H.

J Bone Oncol. 2018 Feb 5;10:49-56. doi: 10.1016/j.jbo.2018.01.003. eCollection 2018 Mar.

22.

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.

Terpos E; International Myeloma Society.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):321-334. doi: 10.1016/j.clml.2018.02.015. Epub 2018 Mar 1. Review.

PMID:
29576386
23.

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.

24.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.

Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G.

J Med Econ. 2018 May;21(5):525-536. doi: 10.1080/13696998.2018.1445634. Epub 2018 Mar 5.

PMID:
29480139
25.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD.

Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.

PMID:
29429912
26.

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

Cavo M, Terpos E, Bargay J, Einsele H, Cavet J, Greil R, de Wit E.

Expert Rev Hematol. 2018 Mar;11(3):219-237. doi: 10.1080/17474086.2018.1437345. Epub 2018 Feb 16.

PMID:
29415570
27.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

PMID:
29386197
28.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

29.

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA.

Blood Cancer J. 2018 Jan 12;8(1):7. doi: 10.1038/s41408-017-0037-4. Review.

30.

Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E.

Blood Adv. 2017 Feb 27;1(7):449-454. doi: 10.1182/bloodadvances.2016003269. eCollection 2017 Feb 28.

31.

Re: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report.

Tournis S, Michopoulos S, Makris K, Terpos E.

J Bone Miner Res. 2018 Mar;33(3):543-545. doi: 10.1002/jbmr.3372. Epub 2018 Feb 2. No abstract available.

PMID:
29281128
32.

Periostin and sclerostin levels in juvenile Paget's disease.

Polyzos SA, Makras P, Anastasilakis AD, Mintziori G, Kita M, Papatheodorou A, Kokkoris P, Terpos E.

Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):269-271. doi: 10.11138/ccmbm/2017.14.2.269. Epub 2017 Oct 25.

33.

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.

Tsakiri EN, Terpos E, Papanagnou ED, Kastritis E, Brieudes V, Halabalaki M, Bagratuni T, Florea BI, Overkleeft HS, Scorrano L, Skaltsounis AL, Dimopoulos MA, Trougakos IP.

Sci Rep. 2017 Dec 19;7(1):17802. doi: 10.1038/s41598-017-17596-4.

34.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

35.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P.

Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7. Review.

36.

Rare manifestations of extramedullary myeloma: testicular plasmacytomas.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Eleftherakis-Papaiakovou E, Kastritis E, Terpos E, Dimopoulos MA.

Leuk Lymphoma. 2018 Aug;59(8):2002-2004. doi: 10.1080/10428194.2017.1410887. Epub 2017 Dec 7. No abstract available.

PMID:
29214871
37.

The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.

Anagnostis P, Vakalopoulou S, Christoulas D, Paschou SA, Papatheodorou A, Garipidou V, Kokkoris P, Terpos E.

Haemophilia. 2018 Mar;24(2):316-322. doi: 10.1111/hae.13384. Epub 2017 Dec 1.

PMID:
29194852
38.

Biology and treatment of myeloma related bone disease.

Terpos E, Christoulas D, Gavriatopoulou M.

Metabolism. 2018 Mar;80:80-90. doi: 10.1016/j.metabol.2017.11.012. Epub 2017 Nov 23.

PMID:
29175022
39.

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.

Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, Dimopoulos MA.

Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22. No abstract available.

PMID:
29167176
40.

An overview of the role of carfilzomib in the treatment of multiple myeloma.

Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA.

Expert Opin Pharmacother. 2017 Dec;18(17):1883-1897. doi: 10.1080/14656566.2017.1404575. Epub 2017 Nov 20. Review.

PMID:
29134824
41.

Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation.

Boutsikas G, Terpos E, Papatheodorou A, Tsirkinidis P, Tsirigotis P, Meletiou A, Lalou E, Telonis V, Zannou A, Kanellopoulos A, Galani Z, Stefanou A, Tsaftaridis P, Viniou NA, Panayiotidis P, Kyrtsonis MC, Meletis J, Vassilakopoulos TP, Angelopoulou MK.

Eur J Haematol. 2018 Feb;100(2):131-139. doi: 10.1111/ejh.12990. Epub 2017 Dec 4.

PMID:
29105864
42.

Increased expression of platelet derived growth factor receptor β on trephine biopsies correlates with advanced myeloma.

Bilalis A, Pouliou E, Roussou M, Papanikolaou A, Tassidou A, Economopoulos T, Terpos E.

J BUON. 2017 Jul-Aug;22(4):1032-1037.

PMID:
28952224
43.

Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL).

Boutsikas G, Terpos E, Markopoulos A, Papatheodorou A, Stefanou A, Georgiou G, Galani Z, Komninaka V, Telonis V, Anagnostopoulos I, Dimitrakopoulou L, Anargyrou K, Tsionos K, Christoulas D, Gonianaki M, Giannikos T, Kokoris S, Konstantopoulos K, Meletis J, Angelopoulou MK, Travlou A, Vassilakopoulos TP.

J BUON. 2017 Jul-Aug;22(4):1022-1031.

PMID:
28952223
44.

Mechanisms of bone destruction in multiple myeloma.

Terpos E, Christoulas D, Gavriatopoulou M, Dimopoulos MA.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12761. Epub 2017 Sep 21. Review.

PMID:
28940410
45.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

46.

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis.

Kostopoulos IV, Paterakis G, Pavlidis D, Kastritis E, Terpos E, Tsitsilonis OE, Papadhimitriou SI.

Blood Cancer J. 2017 Aug 25;7(8):e597. doi: 10.1038/bcj.2017.77. No abstract available.

47.

Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.

Eleutherakis-Papaiakovou E, Dimopoulos MA, Kastritis E, Christoulas D, Roussou M, Migkou M, Gavriatopoulou M, Fotiou D, Panagiotidis I, Ziogas DC, Kanellias N, Papadimitriou C, Terpos E.

Bone Marrow Transplant. 2017 Nov;52(11):1537-1542. doi: 10.1038/bmt.2017.172. Epub 2017 Aug 14.

PMID:
28805791
48.

Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study.

Terpos E, Gobbi M, Potamianou A, Lahaye M, Couturier C, Cavo M.

Eur J Haematol. 2018 Jan;100(1):10-19. doi: 10.1111/ejh.12937. Epub 2017 Oct 30.

PMID:
28801967
49.

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.

Ziogas DC, Terpos E, Gavriatopoulou M, Migkou M, Fotiou D, Roussou M, Kanellias N, Tatouli I, Eleutherakis-Papaiakovou E, Panagiotidis I, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.

Leuk Lymphoma. 2018 Apr;59(4):983-987. doi: 10.1080/10428194.2017.1361031. Epub 2017 Aug 7. No abstract available.

PMID:
28782413
50.

Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.

Terpos E, Matsaridis D, Koutoulidis V, Zagouri F, Christoulas D, Fontara S, Panourgias E, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Moulopoulos LA.

Ann Hematol. 2017 Oct;96(10):1707-1714. doi: 10.1007/s00277-017-3078-7. Epub 2017 Aug 1.

PMID:
28766001

Supplemental Content

Loading ...
Support Center